Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that abietic acid from pine resin more effectively inhibits testosterone 5α-reductase than several plant extracts, suggesting potential for treating androgen-dependent diseases.

This study found that astilbin downregulates effector CD4+ T cell activities through the CYP1B1/ROS/PPARγ pathway, suggesting its potential use in treating inflammation.

This study reported that after 7.5 months of treatment, topical Alfatradiol significantly increased anagen hair rates in women and men with androgenetic alopecia, with minimal side effects.

This article discusses the paradoxical effects of valproic acid on hair, reporting both drug-induced hair loss and the potential for hair growth when used topically, but presents no original research findings.

This study found that torilin from Torilis japonica fruit extract inhibited 5 alpha-reductase in vitro more effectively than alpha-linolenic acid but less effectively than finasteride.

This study characterized the SARM PF-05314882, finding it demonstrates anabolic activity in rats with minimal effects on the prostate, seminal vesicles, and luteinizing hormone levels.

In this study, osthenol was identified as a highly potent inhibitor of 5alpha-reductase type I in LNCaP cells, significantly outperforming finasteride.

Losartan can cause temporary loss of taste.

This study discusses the potential of topical retinoids, vitamin A derivatives, to improve treatment outcomes for androgenetic alopecia by promoting hair growth through extending the anagen phase and stimulating follicular activity, offering a promising approach when combined with existing therapies.

The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.

This article reviews different generations of synthetic retinoids for dermatological use, discussing their efficacy and significant side effects, but reports no new clinical results.

This study found that all-trans retinoic acid (ATRA) negatively affects hair growth by reducing goat dermal papilla cell viability and growth factor expression.

This literature review explored the potential of Rosmarinus Officinalis as a plant-based solution for Androgenetic Alopecia, highlighting its effectiveness and minimal side effects compared to conventional treatments, which often have significant adverse effects.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

This study found that antroquinonol inhibited CD8+ T cell proliferation and reduced proinflammatory cytokine secretion in vitro, while also ameliorating H2O2-induced depigmentation and resisting reductions in hair follicle length, skin thickness, and tyrosinase expression in mice.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

In this study, a novel AR protein degrader was shown to reverse DHT-induced hair regrowth delay in a mouse model of androgenetic alopecia, with minimal circulation and potential side effects.

This study suggests that the use of 5α-reductase inhibitors in men may be associated with macular abnormalities, characterized by cystoid changes and foveal cavitation, potentially progressing to more severe defects.

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

In this study, researchers characterized the retinal structure and function of the Oat^rhg mouse model of gyrate atrophy, finding localized atrophy without significant retina-wide functional impact, suggesting the model may be useful for testing new treatments using multimodal retinal imaging.

This study identified novel 4-Amino-2H-benzo[h]chromen-2-one analogs as potent androgen receptor antagonists that show strong antiproliferative activity against prostate cancer cells, suggesting them as potential lead compounds for therapy development.

This study found that the enzyme encoded by Dgat1 acts as a retinol acyltransferase in murine epidermis, protecting against retinoid toxicity and alopecia by preventing retinol accumulation.

This study used a multi-layer in silico framework to evaluate Korean herbal compounds for androgenetic alopecia, identifying Biochanin A, Saponin Re, and Emodin as potential topical candidates with distinct safety and affinity profiles, although these findings remain purely computational without experimental validation.

This study reported that in rat retinas under high pressure, allopregnanolone synthesis increased and helped reduce pressure-induced damage through GABAA receptors, suggesting potential therapeutic use in glaucoma.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

In this study, researchers found that activating RORA in hair follicle stem cells reduced the expression of cytoskeleton-related genes, affecting cell migration and adhesion, which may aid in understanding hair follicle development and potentially inform alopecia treatments.

This study investigated various synthesized 5-reductase inhibitors and found that compound 6 had the highest anti-androgenic activity and receptor affinity compared to finasteride, showing potential due to its improved efficacy and bioavailability for further research in treating lower urinary tract symptoms.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study found that compounds isolated from Osmanthus fragrans var. aurantiacus demonstrated antioxidative and anti-inflammatory activities, potentially offering therapeutic benefits for inflammatory bowel diseases by inhibiting COX-2 and iNOS enzymes and blocking ERK 1/2 MAPK signaling.